Home > Oncology > ASCO 2021 > Paediatric Cancer > Molecular tumour profiling impacts the diagnosis and treatment of solid tumours

Molecular tumour profiling impacts the diagnosis and treatment of solid tumours

Presented By
Dr Alanna Church , Boston Children’s Hospital, MA, USA
Conference
ASCO 2021
Trial
GAIN/iCAT2
The first results of the GAIN/iCAT2 Consortium trial showed the importance of molecular profiling of solid tumours in young patients. Next-generation sequencing (NGS) assays are now a standard part of clinical care for many adult solid cancers. The significance of molecular tumour profiling for the care of children with cancer is not well understood. To determine the clinical impact of identifying genomic alterations by NGS for young patients with relapsed, refractory, or high-risk extracranial solid tumours, the GAIN/iCAT2 Consortium study (NCT02520713) was started. Dr Alanna Church (Boston Children’s Hospital, MA, USA) reported on the first 389 participants (of estimated 825 patients) in this prospective cohort study enrolling patients at 12 institutions in the USA with extracranial solid tumours diagnosed at age 30 years or less [1]. Targeted DN...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on